Patients with metastatic NSCLC receiving treatment at academic centers (ACs) have an increased 2-year survival compared to patients treated at community-based centers (CCs).
Subsolid nodules (SSN) can be considered a biomarker of lung cancer risk and should be managed with long-term active surveillance.
Significant disparities in the quality of end-of-life lung cancer care were found among racial-ethnic minorities, with higher odds of experiencing potentially preventable medical encounters during end-of-life as compared with non-Hispanic whites.
Elderly patients with stage III non-small cell lung cancer (NSCLC) showed improved overall survival (OS) when treated with chemoradiation (CRT) compared to definitive radiation (RT) alone.
Lung Cancer Clinical Trial Eligibility Criteria and Requirements Have Increased in Number and Complexity
Eligibility criteria continue to increase in number and complexity for lung cancer clinical trials.
DENVER – Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging and treatment in 2016, the International Association for the Study of Lung Cancer (IASLC) announces the second annual publication of “Scientific Advances in Thoracic Oncology,” available online now and in the August 2017 issue of the IASLC’s Journal of Thoracic Oncology (JTO).